Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 expression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
VENTANA PD-L1 (SP142) Assay (15)
PD-L1 IHC 28-8 pharmDx (4)
OncoTect iO® Lung Kit
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
VENTANA PD-L1 (SP142) Assay (15)
PD-L1 IHC 28-8 pharmDx (4)
OncoTect iO® Lung Kit
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
zimberelimab
Sensitive: A1 - Approval
zimberelimab
Sensitive
:
A1
zimberelimab
Sensitive: A1 - Approval
zimberelimab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
pembrolizumab + bevacizumab
Sensitive
:
A1
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
pembrolizumab + bevacizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
PD-L1 expression
Oral Cancer
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oropharyngeal Cancer
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Salivary Gland Cancer
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
Gastric Adenocarcinoma
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Renal Cell Carcinoma
PD-L1 expression
Renal Cell Carcinoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login